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INTRODUCTION 
Oral colon-specific drug delivery systems have recently 
gained importance for delivering a variety of therapeutic 
agents. The major obstacles in delivering drugs to the 
colon are the absorption and degradation pathways in the 
upper gastrointestinal tract. However, a successfully 
designed colon-targeted system can overcome these 
obstacles. Colon targeting has proven beneficial for local 
action in a variety of disease conditions, such as 
inflammatory bowel disease, irritable bowel syndrome and 
colonic cancer. Colon targeting has also proven useful for 
systemic action of protein-peptide drugs such as insulin, 
calcitonin, and met-enkaphalin and even for other 
nonpeptide drugs such as cardiovascular and antiasthmatic  
agents
1
. 
Oral colon delivery is currently considered important not 
only for the treatment of local pathologies, such as 
primarily in flammatory bowel d isease (IBD), but also as a 
means of accomplishing systemic therapeutic goals. 
Accordingly, it has been under extensive investigation as a 
possible strategy to improve the oral bioavailab ility of 
peptide and protein drugs
2
.This manuscript brings to 
account various approaches for targeting orally  
administered dosage forms to the colon and physiological 
issues encountered during targeting. 
1.1 Challenges in the colon targeting of drugs: A drug 
formulat ion when moves from mouth to colon encounters 
various physiological and histological challenges . Also, 
drug absorption from the colon has its own limitations and 
are discussed below. 
1.1.1    Physiological issues:  
a) pH: The most common physiological factor considered 
in the design of delayed release colonic formulations is pH 
gradient of the GIT. It is highly desirable for pH-
dependent colonic formulations to maintain their physical 
and chemical integrity during passage through the stomach 
and small intestine and reach the large intestine where the 
coat should disintegrate to release the drug locally. It 
should however be noted that GI fluids might pass through 
the coat while the dosage form transits through the small 
intestine. This could lead to premature drug release in the 
upper parts of GIT and as a result loss of therapeutic 
efficacy may occur. To overcome these problem higher 
coating levels of enteric polymers is to be applied. 
However, this also allow sinflux of GI flu ids through the 
coat and the thicker coat soften rupture under the influence 
of contractile activity in the stomach
3
.The pH of different 
regions of GIT are shown in Figure 1.  
b) Enzymes: The human colon is a dynamic and 
ecologically diverse environment, containing over 400 
distinct species of bacteria witha population of 10
11
 to 10
12
 
CFU/mL with bacteroides, bifidobacterium, eubacterium, 
lactobacillus etc., greatly out numbering other 
species.These bacteria produce a wide spectrum of 
enzymes that, being reductive and hydrolytic in nature, are 
actively involved in many processes in the colon, such as 
carbohydrate and protein fermentation, bile acid and 
steroid transformation, metabolis m of xenobiotic 
substances, as well as the activation and destruction of 
potential mutagenic metabolites
4
. Figure 2 en lists various 
reductive and hydrolytic enzymes in co lon. 
c)  Motility of colon/ Transit time: The transit time is 
highly variable and influenced by a number of factors like 
diet (in part icular, dietary fiber content), mobility, stress, 
drugs, and disease status. Colonic transit times ranged 
from 50 to 70 hours
5
. Colonic contractile act ivity can be 
described by irregular alternation of quiescence, 
prevalence of non-propagating, segmental contractions and 
infrequent occurrence of propagated contractions that can 
be further classified into low amplitude (the amplitude <50 
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mmHg) and high amplitude propagated contractions (the 
amplitude  >100 mmHg). The occurrence of low amplitude 
propagated contractions is rather frequent (on an average, 
more than 100 times per day) and high amplitude 
propagated contractions are reported to be in the range of 4 
to 12 times per day in healthy subjects, usually upon 
awakening in the morning and post prandial
6
. 
 
Figure 1: pH in different regions of GIT 
 
Figure 2: List of reductive and hydrolytic enzymes in 
colon 
d) Drug release rate/ drug dissolution: It is thought to be 
decreased in the colon, which is attributed to the fact that 
less fluid is present in the colon than in the small 
intestine
7
. The poor dissolution and release rate may in  
turn lead to lower systemic availab ility of drugs. These 
issues could be more problemat ic when the drug candidate 
is poorly water-solubleor require higher doses for therapy. 
Consequently, such drugs need to be delivered in a 
presolubilized form or formulation and then should be 
targeted for proximal colon, which has more flu id than in 
the distal colon
8
. Likewise, colonic formulations for polar 
drugs including proteins and peptides require use of 
absorption enhancing agents (also known as absorption 
promoters). 
e) Biodegradation: The primary source of nutrition for 
these anaerobic bacteria is carbohydrates such as  non-
starch polysaccharides (i.e. dietary fibers) from the 
intestinalchime. It is well established that non-starch 
polysaccharides are fermented during transit through the 
colon and the break down in the stomach and small 
intestine is negligible. Enzymes  responsible for the 
degradation of polysaccharides include α-
larabinofuranosidase, β-D-fucosidase, β-D-galactosidase, 
β-Dglucosidase, β-xylosidase, with the last three enzymes 
being the most active
4
. 
f) Disease status of colon: An immediate issue for 
targeted delivery systemsis site of the disease in the 
patient. IBD is comprised of two specific conditions: 
ulcerative colitis (UC) and crohn’s disease (CD). In UC, 
sites of inflammat ion extend to the more proximal regions 
of the colon over time. In CD, the predominant site of 
inflammat ion is the distal ileum; between 30% and 40% of 
patients also have significant colonic involvement
9
. Figure 
3 summarizes all the physiological barriers encountered 
while targeting drugs to colon and Table 1 shows the 
various drugs used in IBD. 
g) Barriers in colonic absorption:  In the lumen itself, 
specific and nonspecific drug binding occurs through the 
interaction of the drug with dietary components
10
. Non 
selective interactions could occur between regions of the 
glycoprotein drug and undigested food stuffs such as 
waxes and alginates. The mucus layer at the epithelial 
surface, due to it’s highly charged and sieve like nature 
presents a formidable thermodynamic barrier to the transit 
of large, negatively charged drug molecu les. 
Cephalosporins, penicillins and aminoglycosides are few 
examples of s mall molecu le drugs that can bind to 
negatively charged mucus
11
. This might facilitate longer 
colonic residence time and hence environmental or 
enzymatic degradation. Although removal of the mucus 
barrier using mucolytic agents might seem attractive, this 
may implicate in a variety of disease processes and 
pathological conditions due to alteration of intact mucus 
layer. Another barrier to colonic absorption particularly for 
the lipophilic drugs is unstirred water layer present 
between the space of mucus layer and epithelial cells. 
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Figure 3: Summary of physiological barriers encountered while targeting drugs to colon 
Table 1: Various drugs used in inflammatory bowel disease 
Status of disease Drug used Ref 
Ulcerative colitis Glucocorticosteroid 
Salicylates 
Infliximab 
12 
13 
14 
Crohn’s disease Clarithromycin, rifabutin, and clofazimin  
Tacrolimus  
Adalimumab 
15 
16 
17 
Irritable bowel 
syndrome 
Renzapride 
Asimadoline 
Tegaserod Maleate 
18 
19 
20 
Colorectal cancer Oxaliplatin, capecitabine, Bevacizumab, 
irinotecan 
21 
22 
Diverticulitis of 
colon 
Mesalazine and rifaximin 23 
 
1.1.2Histopathological issues: Various stages of colon cancer are discussed in Table 2 
Table 2: Stages of colon cancer
24
 
Stage 0 Intraepithelial or invasion of the lamina propria, no regional lymph node metastasis, no distant metastasis. 
Stage I Tumour invades submucosa; tumour invades muscularispropria, no regional lymph node metastasis, no 
distant metastasis. 
Stage II 
A 
Tumour invades through the muscularis  propria into the subserosa, or into the nonperitonealizedpericolic 
or perirectal t issues, no regional lymph node metastasis, no distant metastasis. 
Stage II 
B 
Tumour d irectly invades other organs or structures and/or perforates the visceral peritoneum, no regional 
lymph node metastasis, no distant metastasis. 
Stage III 
A 
Tumour invades submucosa; tumour invades muscularis  propria, metastasis in regional lymph nodes, no 
distant metastasis. 
Stage III 
B 
Tumour invades through the muscularis  propria into the subserosa, or into the nonperitonealized pericolic 
or perirectal tissues, tumour directly invades other organs or structures and/or perforates the visceral 
peritoneum, metastasis in  regional lymph nodes, no distant metastasis  
Stage III 
C 
Tumour d irectly invades other organs or structures and/or perforates  
the visceral peritoneum , metastasis in more reg ional lymph nodes,no distant metastasis 
Stage IV Tumour d irectly invades other organs or structures and/or perforates  
the visceral peritoneum,metastasis in more regional lymph nodes, distant metastasis 
 
 
 
pH and enzymes 
Motility of colon/Transit time 
Biodegradation & Barriers in colonic absorption  
Drug release rate/Drug dissolution 
Disease status of colon 
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2.1   Approaches to colon s pecific drug delivery 
A variety of approaches have been used and systems
25
have been developed for the purpose of achieving colonic targeting. 
These are included in Figure 4: 
 
Figure 4: Approaches to colon specific drug delivery  
1. Systems developed with pH sensitive polymer: The 
pH in the gastrointestinal tract varies widely 
26
.Use of pH-
dependent polymers is based on the differences in pH 
levels. The polymers described as pH-dependent in the 
colon specific drug delivery systems are insoluble at low 
pH levels but become increasingly soluble as pH rises. It is 
highly desirable for pH-dependent colonic formulat ions to 
maintain their physical and chemical integrity during 
passage through the stomach and small intestine and reach 
the large intestine where the coat should disintegrate to 
release the drug locally
27
. 
2. Time dependent systems: Time-controlled  
formulat ions for colonic delivery are also delayed-release 
formulat ions in which the delay indelivery of the drug is 
time-based. In these systems, the site of drug release is 
decided by the transit time of a formulation in the GI tract, 
which makes it challenging to develop a formulation in  
order to achieve a precise drug release in the colon. 
Ideally, formulat ions are designed such that the site of 
delivery (i.e . colon) is not affected by the individual 
differences in the gastric emptying time, pH of the 
stomachand small intestine or presence of anaerobic 
bacteria in the colon 
28
. 
The drug release from these systems therefore occurs  after 
a predetermined lag phase, which is precisely programmed 
by selecting a suitable combination of controlled-release 
mechanis ms. In general, time-controlled formulations for 
colonic delivery include apH-dependent (enteric coat) 
component because the transit of a formulation in the GI 
tract is largely in fluenced by the gastric emptying time. 
Enteric coating is also used for preventing the rapid 
swelling and disintegration in upper GIT since other 
controlled-release components based on mechanism of 
swelling (gelling), osmosis or a combination of two are 
often included in the time-release formulat ions 
27
. 
3. Enzyme controlled release systems: Microflora  
activated delivery systems are considered to be preferable 
and promising since the abrupt increase of the bacteria 
population and associated enzymat ic activ ities in  
ascending colon represents a non-continuous event 
independent of GI t ransit time and pH 
4
. 
a) Prodrug approach: Prodrug activation may be 
accomplished by the utilization of some specific property 
at the target site, such as altered pH or high activity of 
certain enzymes relative to the non-target tissue, for the 
prodrug-drug conversion 
29
.When synthesizing prodrugs, 
the choice of carrier depends on the functional group 
available on the drug molecule for conjugation with the 
carrier (e.g., the hydroxyl group present on the 
corticosteroids can enter into a glycosidic linkage
30
with 
various sugars,the carboxyl group of biphenylyl acetic acid 
forms anester/amide conjugate with cyclodextrin etc
31
. 
I. Amino-acid conjugates: Proteins and their basic units 
[i.e . the amino-acids (A.A.)] have polar groups like the 
−NH2− and −COOH−. These polar groups are hydrophilic 
and reduce the membrane permeability of A.A and 
proteins 
32
.  
II. Glycoside conjugates: Certain drugs can be conjugated 
to different sugar moieties  to form glycosides. The drug 
part forms the aglycone andis linked to the sugar part, 
which forms the glycone part of the glycoside 
30
. 
III. Glucuronide and sulphate conjugates: Glucuronide 
and sulphate conjugation are the major mechanis ms for the 
inactivation and preparation for clearanceof a variety of 
drugs. Bacteria of the lower GIT, however, secrete β-
glucuronidase and can deglucuronidate avariety of drugs in 
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the intestine. Thus, the deglucuronidation process results in 
the release of the active drug again and enables its 
reabsorption
33
. 
IV Azo-conjugates : The use of these azo compounds 
forcolon-targeting has been in the form of hydrogels as a 
coating material for coating the drug cores and as 
prodrugs
34
. In the colon, the azoreductases cleave the azo 
bond releasing the drug, 5-ASA and the carrier 
sulphapyridine (SP). Due to side effects of SP, another 
approach was used which was based on joining two 
molecules of 5-ASA together to form an ultimate prodrug, 
disodium azodisalicylate (o lsalazine), in which one 
moleculeof 5-ASA is used as a carrier for the other
29
.  
V Polymeric prodrugs: Polymeric prodrugs with drug 
molecule linked direct ly toa high molecular weight 
polymeric backbone. For example the α and β-
cyclodextrins are practically resistantto gastric acid, 
salivary, and pancreatic amylases. Aclinical study has 
shown clear evidence that β-cyclodextrin is poorly 
digested in the small intestine but is almost completely  
degraded by the colonic microflora
35
. In another example 
cyclodextrin derivatization with 17-beta estradiol was 
explored extensively
36
 by Kim et al., 2010. Table 3and 4 
shows some of prodrugs and their colon specific drug 
delivery. 
VI Polysaccharide based approach: The colonicbacteria 
are predominately anaerobic in nature andsecrete enzymes 
that are capable of metabolizing substrates such as 
carbohydrates and proteins that escapethe digestion in the 
upper GIT
37
. Polysaccharides, the polymer of 
monosaccharide retain their integrity because they are 
resistant to the digestive action of gastrointestinal enzymes 
38
. The matrices of polysaccharides are assumed to remain  
intact in thephysiological environment of stomach and 
small intestine but once they are acted upon by the 
bacterial polysaccharidases that results in the degradation 
of the matrices
39
. Limitations associated with the use of 
polysaccharides as drug carriers for colonic delivery are 
that these materials are hydrophilic in nature so they must 
be made water insoluble by cross linking or hydrophobic 
derivatisation
40
. Table 5 en lists a number of 
polysaccharides used for the colon drug delivery.  
Table 3: Prodrugs evaluated for colon s pecific drug delivery and their in vi tro/in vivo performance  
Carrier Drug investigated Linkage hydrolysed Model(s) used Ref 
                                                         Saccharide carriers  
Glucose 
Glycosylated nanocarriers  
Dexamethasone 
Genes 
Glycosidic linkage 
Glycosidic linkage 
Guinea pig  
In vitro  
47 
48 
Amino acid conjugates 
Tyrosine/methionine 
L/D-Alan ine 
19 amino acid conjugates of abscisic acid  
Salicylic acid 
Salicylic acid 
Abscisic acid 
Amide linkage  
Amide linkage  
Amide linkage  
Rabbit  
In vitro  
In vitro/In plant 
49 
50 
51 
Azo conjugates  
Sulphapyridine  
p-Aminobenzoyl -β- alan ine 
Polyurethanes with azo aromat ic groups  
Azo-dextran polymer  
 
Azo linkage with sulphasalazine  
5-ASA  
5-ASA  
Fluorecein isothiocynate 
Rhodamine, Aspirin 
 
5-ASA with essential 
amino acids  
Azo-linkage 
Azo-linkage 
Azo-dextran linkage 
Azobenzene ( N=N 
trans–cis isomerization 
Azo- linkage 
Man  
Man 
In vitro  
In vitro  
 
In vitro  
Rat  
52 
53 
54 
55 
 
56 
Glucuronide  conjugates 
Glucuronic acid  
Methyl 1-O-trichloroacetimidoyl-2,3,5-
tri-O-isobutyryl-α-d-glucopyran-uronate 
Naloxone/ Nalmefene 
Soraprazan  
Glucuronide linkage  
Glucuronide  
linkage 
Rat  
In vitro  
 
57 
58 
 
 
4. Pressure dependent systems: Viscosity of the luminal 
contents within the colon is greater than at other sites 
within the GIT due to the reabsorption of water from the 
large intestine. This change in viscosity leads to an 
increase in pressure resulting from the peristaltic forces. 
This pressure change can be used to trigger drug release 
41
. 
a) Osmotic Controlled Drug Delivery (ORDS-CT): 
Push-pull OROS-CT system comprises of 5 push-pull units 
encapsulated within a hard gelatin capsule. Each push pull 
unit is a bilayered laminated structure containing an 
osmotic push layer and a drug layer, both surrounded by a 
semipermeable layer. An orifice is laser drilled into the 
semipermeable membrane to the drug layer. The outside 
surface of the semipermeable membrane is then coated by 
Eudragit S-100 to delay the drug release from the device 
during its transit through the stomach. Upon arrival in the 
small intestine, the coating dissolves at a pH ≥7. As a 
result, water enters the unit causing the osmotic push 
compartment to swell forcing the drug out of the orifice 
into the colon. The drug release kinetics is precisely  
controlled by the rate of influx of water through the 
semipermeable membrane 
42,43
. 
b) Pressure-controlled colon delivery capsule (PCDC):  
It is made up of ethyl cellu lose that has been developed to 
target the drugs to the colon. The PCDC is composed of 
drug, dispersed in a suppository base, and coated with 
hydrophobic polymer and ethyl cellu lose. Once 
swallowed, the temperature of the body causes the 
suppository base to melt and increase in volume and the 
system resembles a liquid-filled ethyl cellulose balloon. 
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The balloon is able to withstand the luminal pressure of the 
small intestine resulting from peristalsis, but will rupture 
when subject to the pressure of more intense contractions 
of the colon and contents of thicker v iscosity 
44
. 
Novel Colon Targeted Deli very System (CODESTM):  
CODESTM is a unique CDDS technology that was 
designed to avoid the inherent problems associated with 
pH or time dependent systems
45
. CODESTM is a 
combined approach of pH dependent and microbially  
triggered CDDS. It has been developed by utilizing a 
unique mechanism involving lactulose, which acts as a 
trigger for site specific drug release in the colon. The 
system consists of a traditional tablet core containing 
lactulose, which is over coated with and acid soluble 
material, Eudragit E, and then subsequently overcoated 
with an enteric material, Eudragit L. The premise of the 
technology is that the enteric coating protects the tablet 
while it is located in the stomach and then dissolves 
quickly following gastric emptying. The acid soluble 
material coating then protects the preparation as it passes 
through the alkaline pH of the small intestine. Once the 
tablet arrives in the colon, the bacteria enzymatically  
degrade the polysaccharide (lactulose) into organic acid. 
This lowers the pH surrounding the system sufficient to 
affect the dissolution of the acid soluble coating and 
subsequent drug release 
46
. The summary of the stratergies 
are given in Tab le 6 A and 6 B. 
Table 4: Prodrugsevaluated for colon s pecific drug delivery and their in vitro/in vivo performance(Continued)  
Carrier Drug investgated Linkage hydrolysed Model(s) used Ref 
Cyclodextrin conjugates 
Cyclodextrin  
β-cyclodextrin-poly (4-acry loyl 
morpholine) 
Biphenylyl acetic acid 
Acyclovir 
Ester/amide  
Ester linkage  
 
In vitro  
In vitro  
59 
60 
 
Polymeric prodrugs 
Poly-L-aspartic acid  
Polyamidoaminedendrimer and 
poly(ethylene glycol) 
with or without galactose 
Dexamethasone 
Doxorubicin 
Amide linkage  
Acid-labile hydrazone 
linker 
Rat  
In vitro  
61 
62 
Dextran conjugate  
Dextran  
β-lactoglobulin-dextran maillard 
conjugates 
Naproxen  
Lipid, proteins 
Ester linkage  
Carbohydrate linkage 
Rabbit  
In vitro  
63 
64 
 
Table 5: Polysaccharides investigated for colon s pecific drug delivery with their dosage forms and summary of the 
results obtained 
Polysaccharide investigated Model drug  Dosage form prepared Model (s) used Ref 
Chitosan Insulin 
Sod.diclofenac  
Capsules 
Microspheres 
Rat  
In vitro  
65 
66 
Pectin Indomethacin 
Radioactive tracer 
Resveratrol 
Matrices 
Matrix tablets 
Microparticles 
In vitro  
Man 
In vitro/ rat  
67 
68 
69 
Guar gum Trimetazidine 
dihydrochloride 
Guar gum-based three-
layer matrix tablets 
Man 70 
Sugar cane native dext ran Lobenzarit disodium and 
propranolol hydrochloride 
Compressed tablets In vitro  71 
Methacrylated inulin      _ Crosslinked hydrogels In vitro  72 
Chondroitin sulfate      _ Matrix tablet In vitro  73 
Starch Radioactive tracer Enteric-coated capsules Man 74 
Amylose/ethyl cellu lose  (1:4) Glucose Coated cores Man 75 
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Table 6 A: Summary of formulation evaluation of colon targeting drug delivery systems when various approaches 
were used 
Polymers Drug 
investigated 
Dosage 
form 
Model 
(s) used 
Performance of the system Ref 
pH dependent system 
Alginate–guar gum 
hydrogel crosslinked with 
glutaraldehyde 
 
 
Dib lock copolymers of 
polyethylene glycol and t-
butyl methacrylate, ethyl 
acrylate or n-butyl 
acrylate  
 
 
Two methacrylic acid  
copolymers – Eudragit  
L100 and Eudragit S100. 
 
 
Protein model  
( BSA) 
 
 
 
Indomethacin 
Fenofibrate 
 
 
 
 
 
Tegaserod 
maleate (TM) 
 
 
 
Hydrogel 
 
 
 
 
Emulsion 
 
 
 
 
 
 
Tablet 
 
 
 
 
In vitro  
 
 
 
 
In vitro  
 
 
 
 
 
 
In vitro/ 
beagle 
dog 
Guar gum and glutaraldehyde 
crosslinking increases entrapment 
efficiency and prevents the rapid 
dissolution of alginate in higher pH of 
the intestine. 
Drug release from pH-sensitive 
supramolecular assemblies increased 
with pH shift from 1.2 to 7.2. Such  
pH-sensitive self-assemblies can be 
potentially useful to enhance the oral 
bioavailability of poorly water-soluble 
drugs. 
The results of the present study have 
demonstrated that the pH-dependent 
tablet system is a promising vehicle for 
preventing rapid hydrolysis in gastric 
milieu and improving oral 
bioavailability of TM for the treatment 
of irritable bowel syndrome. 
76 
 
 
 
 
77 
 
 
 
 
 
 
78 
 
 
Time dependent system 
Pectin–4-aminothio 
phenol (Pec–ATP) 
 
 
Eudragit NE 30 D (inner 
coating) &Opadry OY-P-
7171 (outer coating) 
 
 
 
Pectin and chitosan 
 
Metronidazole 
(Met) 
 
 
Sophoraflavesc
ensaiton (ASF, 
extracts 
 
 
 
Metronidazole  
Microparticl
es 
 
 
Tablet 
coated      
 
 
 
 
Compressio
n coated 
tablet 
 
In vitro  
 
 
 
In vitro/ 
dog 
 
 
 
 
In vitro/ 
rat 
34.4-fo ld more (met) is retarded in  
Pec–ATP microparticles within 6 h  
compared to control particle.  
 
ASF wax-matrix tablets coated with 
Eudragit NE 30 D and Opadry OY-P-
7171 using the regular coating 
technique could be designed to achieve 
a lag time of 3 h in the small intestinal 
tract. 
Selective delivery of metronidazole to 
the colon could be achieved using a 
pectin or pectin chitosan mixture in the 
form of compression coated tablets. 
 
79 
 
 
 
80 
 
 
 
 
 
81 
Time and pH dependent systems 
Eudragit S-100 and 
Poly(dl-lact ide-co-
glycolide) (PLGA) 
 
 
Eudragit RS 30D and 
Eudragit L 55 30D 
 
Eudragit L-100 and S-100 
(1:2) 
 
 
 
 
Budesonide 
 
 
 
 
Indomethacin 
 
 
Theophylline 
 
 
 
 
 
Microparticl
es 
 
 
 
 
Minitablets 
 
 
Microcapsul
es 
 
 
 
 
 
In vitro  
 
 
 
 
In vitro/ 
human 
 
In vitro/ 
rat 
 
 
 
 
Application of double 
microencapsulation technique 
employing PLGA matrix and Eudragit  
S-100 coating shows promise for site 
specific and controlled delivery of 
budesonide in crohn’s disease. 
Absorption of indomethacin from min i 
tablets with colon release occurs after 
a lag time of 2.5-3 h. 
Pulsatile drug release over a period of 
2–24 h, consistent with the 
requirements for 
chronopharmaceutical drug delivery 
was achieved from insoluble gelatin 
capsules, in which microencapsulated 
theophylline was sealed by means of a 
suitable hydrogel plug. 
 
82 
 
 
 
 
83 
 
 
84 
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Table 6 B: Summary of formulation evaluation of colon targeting drug delivery systems when various approaches 
were used 
Polymers Drug  Dosage form Model 
used 
Performance of the system Ref 
Microflora activated system 
Pectin (PT) 
 
 
Eudragit FS30D 
Guar gum 
 
 
 
 
 
 
Amylose and 
ethylcellulose 
 
Ketoprofen 
(KP) 
 
Budesonide 
 
 
 
 
 
 
 
5-amino 
salicylic acid  
Synthetically 
dried residue 
 
Pellets 
 
 
 
 
 
 
 
Pellets 
 
In vitro/ 
rat 
 
In vitro/ 
rat 
 
 
 
 
 
 
In vitro/ 
rat 
 
Enzyme-dependant PT-KP prodrug  and 
the time required to reach the maximum 
drug level was 8 h. 
Polymer mixture coated formulat ion also 
concluded that formulat ion was found to be 
stable to acid environment of stomach and 
formulat ion was reached to ileocecal 
junction within 5th h and at 7th h of study 
the formulat ion indicating the dissolution 
of polymer coat in colon to release the drug 
specifically in colon. 
Digestion of mixed amylose and 
ethylcellulose films was proportional to the 
quantity of amylose present in the film. 
Drug release from coated pellets was 
accelerated in the presence of the enzyme.  
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Thickness of ethyl cellulose film is an 
important factor in disintegrating of the 
formulat ion 
PCDCs disintegrate in the colon due to 
luminal pressures and peristalsis was 
evaluated by a PK study involving the 
salivary excretion of caffeine after oral 
administration of PCDC to human subjects, 
the mean thickness of the EC coating 
membrane was 50±1 μm and of which 
mean hardness was 2.08±0.15 newton was 
thought to deliver caffeine into the human 
colon. 
Delayed release was attributed to the 
formation of a zinc phosphate coating in 
vitro and in vivo inducing the retention of 
theophylline release. Zn-pectinate beads 
exhibit interesting properties due to its 
potential as pulsatile delivery system 
induced by the in situ format ion of Zn 
phosphate, while Ca-pectinate was found to 
be of limited suitability for controlled 
release of theophylline. 
Disintegration time depended on the weight 
fraction of the core tablet, and the drug 
release rate after d isintegration increased 
with increasing drug concentration in the 
core tablet. Time required for 50% drug 
release and the disintegration time was 
linear 
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FUTURE PROSPECTS:  
The colon has captured attention as a site for the delivery 
of drugs because of its greater responsiveness to 
absorption enhancers, protease inhibitors, and novel 
bioadhesive and biodegradable polymers. Although the 
success rate of these approaches, when used alone is pretty 
low, when used in combinations, these agents have 
demonstrated wonders in increasing the drug 
bioavailability. The development of a dosage form that 
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improves the oral absorption of peptide and protein drugs 
whose bioavailability is very low because of instability in 
the GI tract (due to pH or enzymatic degradation) is one of 
the greatest challenges for oral peptide delivery in the 
pharmaceutical field. Colon targeted mult iparticulate 
systems like microspheres and nanoparticles can provide a 
platform for spatial delivery of candidates like peptides, 
proteins, oligonucleotides and vaccines. The 
bioavailability of protein drugs delivered at the colon site 
needs to address. Studies on drug absorption by the 
intestinal system have focused on drug transporters that 
mediate drug influx and efflux and agents which can 
enhance drug absorption. The colon segment is designed 
by nature mainly to expel metabolis m products rather than 
to absorb nutrients. Therefore, more research that is 
focused on the specificity of drug uptake at the colon site 
is necessary. Such studies will be significant in advancing 
the cause of colon targeted delivery of therapeutics in 
future. 
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